

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/089,020	03/27/2003	Amarjit Singh	U 013943-5	9010
140 75	10/23/2006	,	EXAMINER	
LADAS & PARRY			PRYOR, ALTON NATHANIEL	
26 WEST 61ST NEW YORK, 1	-		ART UNIT	PAPER NUMBER
,	•		1616	
			DATE MAILED: 10/23/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

•	Application No.	Applicant(s)			
	10/089,020	SINGH ET AL.			
Office Action Summary	Examiner	Art Unit			
	Alton N. Pryor	1616			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONED	ely filed the mailing date of this communicati (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 25 Ju	ly 2006.				
2a)⊠ This action is FINAL . 2b)☐ This	action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	3 O.G. 213.			
Disposition of Claims					
4) Claim(s) 1,2,4-11 and 15 is/are pending in the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) 1,2,4-11,15 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or	vn from consideration.				
Application Papers					
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the of Replacement drawing sheet(s) including the correction of the original transfer of the contraction of the original transfer of the contraction of the contract	epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	37 CFR 1.85(a). ected to. See 37 CFR 1.121	(d).		
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Application ity documents have been receive (PCT Rule 17.2(a)).	on No d in this National Stage			
Attachment(s)					
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary (Paper No(s)/Mail Da 5) Notice of Informal Pa 6) Other:	te			

DETAILED ACTION

Applicant's arguments filed 7/25/06 have been fully considered but they are not persuasive. See argument below.

Rejection of claims 1,2,4-11, and 15 under 35 USC 103(a) as being obvious over
 WO 99/12524 will be maintained in light of amendment filed 7/25/06 for reason
 on record and reason as follows.

Applicant argues:

A broad number of NSAIDs is disclosed in WO '524, but only lornoxicam multi-unit compositions have been exemplified.
 Nowhere in WO '524 is there teaching or motivation to make a tablet comprising nimesulide wherein nimesulide is present in the fast release layer and in the extended release layer.

Examiner argues:

b) WO '524 teaches numerous NSAIDs including nimesulide that can be present in both the fast and extended release portions of the multi-unit composition. See claims 1,11,12. It is important to note that WO '524 is not required to exemplify all NSAID's enclosed therein. However, the general teaching of WO' 524 suggests that all NSAID's disclosed therein can be formulated into a multi-unit composition wherein the same NSAID can be present in both the fast and extended release layers; thus, a reading of the examples to lornoxicam does not limit the invention to multi-unit compositions

comprising only lornoxicam. With respect to the dosage form, WO '524 may not specifically teach compression of the multi-unit composition. However, WO '524 discloses that the multi-unit composition can be formulated into a tablet, which suggests compression of the composition. Examiner reiterates that WO '524 discloses that the multi-unit compositions therein can be formulated into tablets. See page 21 lines 19-21.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Telephonic Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alton N. Pryor whose telephone number is 571-272-0621. The examiner can normally be reached on 8:00 a.m. - 4:30 p.m..

Art Unit: 1616

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter can be reached on 571-272-0646. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Alton Pryor

Primary Examiner

AU 1616